Signalisation JAK/STAT
Les inhibiteurs de la signalisation JAK/STAT sont des composés qui perturbent la voie des kinases Janus (JAK) et du transducteur et activateur de transcription (STAT), impliquée dans la signalisation des cytokines, la croissance cellulaire et la réponse immunitaire. Ces inhibiteurs sont des outils importants pour étudier la régulation de cette voie et son rôle dans diverses maladies, notamment les cancers, les troubles immunitaires et les affections inflammatoires. Les inhibiteurs JAK/STAT sont également en cours de développement en tant que thérapies ciblées pour ces maladies. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de haute qualité de la signalisation JAK/STAT pour soutenir vos recherches en biologie moléculaire, oncologie et immunologie.
Sous-catégories appartenant à la catégorie "Signalisation JAK/STAT"
366 produits trouvés pour "Signalisation JAK/STAT"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
PMMB-187
CAS :PMMB-187, a selective STAT3 inhibitor, exhibits an IC50 of 1.81 μM in MDA-MB-231 cells. This compound induces apoptosis in MDA-MB-231 cells by inhibiting STAT3 transcriptional activity and nuclear translocation, reducing mitochondrial membrane potential, increasing reactive oxygen species (ROS) production, and upregulating the expression of apoptosis-related proteins. PMMB-187 is useful for research in the field of cancer.Formule :C27H23BrN2O6S2Couleur et forme :SolidMasse moléculaire :615.52Ten01
Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37STAT3-IN-7
CAS :STAT3-IN-7, an orally active aryl sulfonamido azetidine compound, serves as a STAT3 inhibitor with anticancer activities.Formule :C30H26F5N5O4SCouleur et forme :SolidMasse moléculaire :647.62STAT3-IN-35
CAS :STAT3-IN-35 is a STAT3 inhibitor that binds to the SH2 domain. This compound inhibits the phosphorylation of STAT3 and exhibits antiproliferative activity in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 has demonstrated toxicity and potent antitumor activity in TNBC xenograft models.Formule :C21H23NO4Couleur et forme :SolidMasse moléculaire :353.41Londamocitinib
CAS :Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Formule :C28H31F2N7O4SDegré de pureté :98.64% - 99.56%Couleur et forme :SolidMasse moléculaire :599.65Ref: TM-T11706
1mg170,00€5mg416,00€1mL*10mM (DMSO)537,00€10mg567,00€25mg858,00€50mg1.108,00€100mg1.485,00€JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Couleur et forme :SolidTyk2-IN-15
CAS :Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].Formule :C21H25F2N7OCouleur et forme :SolidMasse moléculaire :429.47JDTic
CAS :JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63(3R,4S)-Tofacitinib
CAS :(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37JAK2-IN-9
CAS :Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.
Formule :C20H24N6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :412.51JAK-IN-27
CAS :JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM
Formule :C20H21F2N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :413.42STAT3-IN-18
CAS :STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and
Formule :C18H24Cl2N2O6PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :630.38JAK1-IN-10
CAS :JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
Formule :C15H17N7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :295.34JAK-IN-34
CAS :JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,
Formule :C27H26N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :450.53JAK1-IN-11
CAS :JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.
Formule :C26H36N6O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.67DPP
CAS :DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating
Formule :C36H40Cl2N2O10PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :926.7
